Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

Journal of Virology

Volumn 75, Issue 17, 2001, Pages 8340-8347

  Parren, P W H I ^a   Marx, P A ^a   Hessell, A J ^a   Luckay, A ^a   Harouse, J ^a   Cheng Mayer, C ^a   Moore, J P ^a   Burton, D R ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B12; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNITY; IN VITRO STUDY; MACACA; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; HIV; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; MACACA; NEUTRALIZATION TESTS; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VAGINAL DISCHARGE;

EID: 0034864776     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.17.8340-8347.2001     Document Type: Article

References (43)

1. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
2. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
3. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals
4. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
5. Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate
6. Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: Evidence for compartmentalization of HIV-1 between semen and blood
7. Requirement for multiple lymphocyte subsets in protection by a live-attenuated vaccine against retroviral infection
8. Kinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus
9. Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells
10. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
11. Preand post-exposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody
12. Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo
13. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs
14. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells
15. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression
16. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in the rectal and genital secretions of women
17. Secretory immunity in the female reproductive tract
18. Mucosal immunity in the female reproductive tract: Correlation of immunoglobulins, cytokines, and reproductive hormones in human cervical mucus around the time of ovulation
19. Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation
20. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection
21. Immunoglobulin concentrations and antigen-specific antibody levels in cervicovaginal lavages of rhesus macaques are influenced by the stage of the menstrual cycle
22. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency virus (SHIV)
23. Progesterone implants enhance SIV vaginal transmission and early virus load
24. Protection of macaques against pathogenic SHIV-89.6PD by passive transfer of neutralizing antibodies
25. HIV-1 entry at the mucosal surface: Role of antibodies in protection
26. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
27. Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia
28. The anti-viral activity of antibodies in vitro and in vivo
29. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site
30. Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design
31. Neutralization of HIV-1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity
32. Antibody neutralizationresistant primary, isolates of human immunodeficiency virus type 1
33. Quantitative aspects of passive immunity, to respiratory syncytial virus infection in infant cotton rats
34. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
35. IgG surfaces as an important component in mucosal protection
36. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer
37. Cyclic changes of immunoglobulins and specific antibodies in human and rhesus monkey cervical mucus
38. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV1/SIV chimeric virus infections of macaque monkeys
39. Vaginal transmission of SIV: Assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks
40. In vivo adaptation of SHIV(SF162): Chimeric virus expressing a NSI, CCR5-specific envelope protein
41. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
42. Quantification of HIV in semen: Correlation with antiviral treatment and immune status
43. Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12